Supplementary material

Supplementary Table 1. Clinicopathologic characteristics of patients with locally advanced cervical cancer in the NAC group with different cycles.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Before PSM |  | After PSM |  |
| 1 cycle(n = 106) | 2 cycles(n = 140) | 3 cycles(n = 13) | *p* | 1 cycle(n = 99) | 2 cycles(n = 122) | 3 cycles(n = 12) | *p* |
| Age at surgery1 (yr) | 47.32 ± 8.58 | 49.33 ± 8.06 | 47.91 ± 10.16 | 0.176 | 47.63 ± 8.63 | 49.25 ± 8.17 | 48.44 ± 10.41 | 0.371 |
| Resected lymph nodes2 | 30.0 (23.0, 38.0) | 32.0 (26.0, 39.0) | 36.0 (26.0, 47.5) | 0.191 | 30.0 (23.0, 38.0) | 32.0 (25.8, 40.0) | 36.0 (27.8, 48.3) | 0.157 |
| FIGO stage, n (%) |  |
|  | IB3 | 61 (57.5) | 58 (41.4) | 5 (38.5) | 0.032 | 61 (61.6) | 57 (46.7) | 5 (41.7) | 0.060 |
| IIA2 | 45 (42.5) | 82 (58.6) | 8 (61.5) | 38 (38.4) | 65 (53.3) | 7 (58.3) |
| Histology type, n (%)  |
|  | SCC | 95 (89.6) | 129 (92.1) | 10 (76.9) | 0.149 | 88 (88.9) | 112 (91.8) | 9 (75.0) | 0.162 |
| AC | 11 (10.4) | 9 (6.4) | 3 (23.1) | 11 (11.1) | 9 (7.4) | 3 (25.0) |
| ASC | 0 | 2 (1.4) | 0 | 0 | 1 (0.8) | 0 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Pathology, n (%) |
|  | High differentiated | 5 (4.7) | 5 (3.6) | 1 (7.7) | 0.754 | 4 (4.0) | 2 (1.6) | 1 (8.3) | 0.505 |
| Middle differentiated | 61 (57.5) | 79 (56.4) | 6 (46.2) | 57 (57.6) | 70 (57.4) | 6 (50.0) |
| Low differentiated | 40 (37.7) | 56 (40.0) | 6 (46.2) | 38 (38.4) | 50 (41.0) | 5 (41.7) |
| Undifferentiated | 0 | 0 | 0 | 0 | 0 | 0 |
| LNM, n (%) |
|  | Negative | 87 (82.1) | 114 (81.4) | 10 (76.9) | 0.860 | 80 (80.8) | 97 (79.5) | 9 (75.0) | 0.857 |
| Positive | 19 (17.9) | 26 (18.6) | 3 (23.1) | 19 (19.2) | 25 (20.5) | 3 (25.0) |
| Surgical margin, n (%) |
|  | Negative | 104 (98.1) | 136 (97.1) | 12 (92.3) | 0.397 | 97 (98.0) | 119 (97.5) | 11 (91.7) | 0.341 |
| Positive | 2 (1.9) | 4 (2.9) | 1 (7.7) | 2 (2.0) | 3 (2.5) | 1 (8.3) |
| Parametria, n (%) |
|  | Negative | 105 (99.1) | 137 (97.9) | 13 (100.0) | 0.704 | 98 (99.0) | 119 (97.5) | 12 (100.0) | 0.701 |
| Positive | 1 (0.9) | 3 (2.1) | 0 | 1 (1.0) | 3 (2.5) | 0 |
| LVSI, n (%)  |
|  | Negative | 1 (0.9) | 1 (0.7) | 0 | 0.206 | 1 (1.0) | 1 (0.8) | 0 | 0.207 |
| Positive | 6 (5.7) | 14 (10.0) | 3 (23.1) | 6 (6.1) | 13 (10.7) | 3 (25.0) |
| Unknown | 99 (93.4) | 125 (89.3) | 10 (76.9) | 92 (92.9) | 108 (88.5) | 9 (75.0) |
| Stromal invasion, n (%) |
|  | Inner 1/3 | 28 (26.4) | 38 (27.1) | 2 (15.4) | 0.385 | 27 (27.3) | 34 (27.9) | 2 (16.7) | 0.482 |
| Middle 1/3 | 29 (27.4) | 35 (25.0) | 1 (7.7) | 27 (27.3) | 31 (25.4) | 1 (8.3) |
| Outer 1/3 | 49 (46.2) | 67 (47.9) | 10 (76.9) | 45 (45.5) | 57 (46.7) | 9 (75.0) |

1Age at surgery (years) data are mean ± SD. The statistical method is one-way ANOVA.

2Resected lymph nodes are median (the 25th percentile, the 75th percentile). The statistical method is Kruskal-Wallis H test.

NAC, neoadjuvant chemotherapy; PSM, propensity score matching; FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous carcinoma; LNM, lymph node metastasis; LVSI, lymphovascular space invasion.